CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

Inclusion Criteria: 1. the patients must be patients with relapsed or refractory CD7 Positive T cell-derived malignancies, who have at least one course of standard regimen chemotherapy and one course of salvage regimen chemotherapy and have poor effect; 2. Researchers believe that there is no other feasible and effective alternative treatment, such as hematopoietic stem cell transplantation; 3. Patients should have indicators for detection or evaluation of disease, including detection of minimal residual disease (MRD) by immunophenotyping, cytogenetics or PCR; 4. They are 14-70 years old, regardless of gender or race; 5. Physical condition: ECoG score 0-2; 6. Cardiac function: left ventricular ejection fraction greater than or equal to 40%; 7. The expected survival time was \> 12 weeks; 8. Serum creatinine (CR) ≤ 1.5 × ULN (upper limit of normal value), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, total bilirubin ≤ 1.5 × ULN; 9. Patients have self-knowledge ability and can sign informed consent; 10. The guardian of the child patient agreed to sign the informed consent. Exclusion Criteria: 1. pregnant or lactating women; 2. Uncontrolled infection; 3. Active HBV or HCV infection; 4. People living with HIV; 5. Less than 100 days after allogeneic hematopoietic stem cell transplantation; 6. Patients with acute GVHD or chronic GVHD after allogeneic hematopoietic transplantation; 7. Patients receiving GVHD treatment.